摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(4-chlorophenyl)-N'-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)urea | 59440-79-8

中文名称
——
中文别名
——
英文名称
N-(4-chlorophenyl)-N'-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)urea
英文别名
1-(4-chloro-phenyl)-3-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-urea;N1-(Phenazon-4-yl)-N2-p-chlorphenylharnstoff;1-(4-chlorophenyl)-3-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)urea;1-(4-chlorophenyl)-3-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)urea
N-(4-chlorophenyl)-N'-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)urea化学式
CAS
59440-79-8
化学式
C18H17ClN4O2
mdl
MFCD00170370
分子量
356.812
InChiKey
SYMZTHSEBKAOLU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    25
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    64.7
  • 氢给体数:
    2
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    4-氨基安替比林对氯苯异氰酸酯乙腈 为溶剂, 以75%的产率得到N-(4-chlorophenyl)-N'-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)urea
    参考文献:
    名称:
    Lattmann, Eric; Sattayasai, Jintana; Boonprakob, Yodchai, Arzneimittel-Forschung/Drug Research, 2005, vol. 55, # 5, p. 251 - 258
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL UREIDO - AND AMIDO-PYRAZOLONE DERIVATIVES<br/>[FR] NOUVEAUX DERIVES DE L'UREIDO-PYRAZOLONE ET DE L'AMIDO-PYRAZOLONE
    申请人:UNIV ASTON
    公开号:WO2004106306A1
    公开(公告)日:2004-12-09
    The present invention provides compounds of formula (I); wherein each of R1 to R4 is independently selected from hydrogen, a halogen, a substituted or unsubstituted cyclic and heterocyclic moiety, substituted or unsubstituted, linear or branched alkyl, alkyloxy, alkylcarbonyl, alkyloxycarbonyl, alkenyl, alkenyloxy, alkenylcarbonyl, alkenyloxycarbonyl, alkynyl, alkynyloxy, alkynylcarbonyl, alkynyloxycarbonyl, aryl, benzyl, arlyoxy, arylcarbonyl, aryloxycarbonyl and sulphur equivalents of said oxy, carbonyl and oxycarbonyl moieties, and A is NH, or (CH2)n, where n is preferably 0, 1 or 2. The invention also relates to methods for preparing the compounds and their uses as CCK receptor ligands and CCK antagonists.
    本发明提供了化合物的结构公式(I);其中R1至R4中的每一个均独立地选自氢、卤素、取代或未取代的环状和杂环状基团、取代或未取代的直链或支链烷基、烷氧基、烷基羰基、烷氧羰基、烯基、烯氧基、烯基羰基、烯氧羰基、炔基、炔氧基、炔基羰基、炔氧羰基、芳基、苄基、芳氧基、芳基羰基、芳氧羰基以及上述氧、羰基和氧羰基基团的等效物,A为NH,或(CH2)n,其中n优选为0、1或2。该发明还涉及制备这些化合物的方法以及它们作为CCK受体配体和CCK拮抗剂的用途。
  • Novel ureido-and amido-pyrazolone derivatives
    申请人:Lattmann Eric
    公开号:US20070185115A1
    公开(公告)日:2007-08-09
    The present invention provides compounds of formula (I); wherein each of R 1 to R 4 is independently selected from hydrogen, a halogen, a substituted or unsubstituted cyclic and heterocyclic moiety, substituted or unsubstituted, linear or branched alkyl, alkyloxy, alkylcarbonyl, alkyloxycarbonyl, alkenyl, alkenyloxy, alkenylcarbonyl, alkenyloxycarbonyl, alkynyl, alkynyloxy, alkynylcarbonyl, alkynyloxycarbonyl, aryl, benzyl, arlyoxy, arylcarbonyl, aryloxycarbonyl and sulphur equivalents of said oxy, carbonyl and oxycarbonyl moieties, and A is NH, or (CH 2 ) n , where n is preferably 0, 1 or 2. The invention also relates to methods for preparing the compounds and their uses as CCK receptor ligands and CCK antagonists.
    本发明提供了式(I)的化合物;其中R1至R4中的每个独立地选择自氢、卤素、取代或未取代的环状和杂环状基团、取代或未取代的线性或支链烷基、烷氧基、烷基羰基、烷氧基羰基、烯基、烯氧基、烯基羰基、烯氧基羰基、炔基、炔氧基、炔基羰基、炔氧基羰基、芳基、苄基、芳氧基、芳基羰基、芳氧基羰基以及所述氧、羰基和氧羰基基团的等效物,且A为NH或(CH2)n,其中n最好为0、1或2。本发明还涉及制备该化合物的方法以及它们作为CCK受体配体和CCK拮抗剂的用途。
  • Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents
    作者:Roland W. Bürli、Han Xu、Xiaoming Zou、Kristine Muller、Jennifer Golden、Mike Frohn、Matthew Adlam、Matthew H. Plant、Min Wong、Michele McElvain、Kelly Regal、Vellarkad N. Viswanadhan、Philip Tagari、Randall Hungate
    DOI:10.1016/j.bmcl.2006.04.068
    日期:2006.7
    We report the discovery of potent agonists for the human formyl-peptide-like 1 receptor (hFPRL1). These compounds did not act at a closely related receptor denoted human formyl peptide receptor (hFPR) up to 10 mu M concentration. Recent studies have indicated that agonizing this receptor may promote resolution of inflammation. In an exploratory study, a novel hFPRL1 agonist showed efficacy in a mouse ear inflammation model following oral administration. (c) 2006 Elsevier Ltd. All rights reserved.
  • FARGHALY A. M., PHARMAZIE, 1979, 34, NO 2, 70-73
    作者:FARGHALY A. M.
    DOI:——
    日期:——
  • NOVEL UREIDO - AND AMIDO-PYRAZOLONE DERIVATIVES
    申请人:Aston University
    公开号:EP1628963A1
    公开(公告)日:2006-03-01
查看更多